Dr Atul Batra speaks to ecancer about the results from a phase II randomised controlled trial evaluating the addition of low-dose pembrolizumab (LDPm) to neoadjuvant chemotherapy (NACT) in patients with stage II-III triple-negative breast cancer (TNBC) in a real-world, resource-constrained setting.

The study found that low-dose pembrolizumab, when added to neoadjuvant chemotherapy, offers a clinically meaningful improvement in pathological complete response copmarable to standard does pembrolizumab and thus may serve as a viable and more accessible immunotherapy strategy for TNBC patients in resource-limited settings.